146 related articles for article (PubMed ID: 35417031)
1. Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway.
Tsao AN; Chuang YS; Lin YC; Su Y; Chao TC
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35417031
[TBL] [Abstract][Full Text] [Related]
2. Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer.
Abdalla AN; Qattan A; Malki WH; Shahid I; Hossain MA; Ahmed M
Molecules; 2020 Oct; 25(20):. PubMed ID: 33050377
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
[TBL] [Abstract][Full Text] [Related]
4. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 mediates GDF-15 dependent stemness and intrinsic drug resistance in breast cancer.
Modi A; Purohit P; Roy D; Vishnoi JR; Pareek P; Elhence P; Singh P; Sharma S; Sharma P; Misra S
Mol Biol Rep; 2022 Apr; 49(4):2877-2888. PubMed ID: 35066766
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of FoxM1 by MnSOD Overexpression Contributes to Cancer Stem-Like Cell Characteristics in the Lung Cancer H460 Cell Line.
Fu Z; Cao X; Yang Y; Song Z; Zhang J; Wang Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818789635. PubMed ID: 30111255
[TBL] [Abstract][Full Text] [Related]
7. Dinaciclib inhibits the growth of acute myeloid leukemia cells through either cell cycle-related or ERK1/STAT3/MYC pathways.
Teng CJ; Cheng PT; Cheng YC; Tsai JR; Chen MC; Lin H
Toxicol In Vitro; 2024 Apr; 96():105768. PubMed ID: 38135130
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 facilitates breast cancer cell stemness and migration in YAP1-dependent manner.
Sun HL; Men JR; Liu HY; Liu MY; Zhang HS
Arch Biochem Biophys; 2020 May; 685():108349. PubMed ID: 32209309
[TBL] [Abstract][Full Text] [Related]
9. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
[TBL] [Abstract][Full Text] [Related]
10. Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells.
Wang D; Hu G; Du Y; Zhang C; Lu Q; Lv N; Luo S
J Exp Clin Cancer Res; 2017 Feb; 36(1):23. PubMed ID: 28148279
[TBL] [Abstract][Full Text] [Related]
11. Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.
Buzzetti M; Morlando S; Solomos D; Mehmood A; Cox AWI; Chiesa M; D'Alessandra Y; Garofalo M; Topham CH; Di Leva G
Sci Rep; 2021 Mar; 11(1):5374. PubMed ID: 33686114
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of CDK3 activation by cyclin E1 and inhibition by dinaciclib.
Gui W; Hang Y; Cheng W; Gao M; Wu J; Ouyang Z
Biochem Biophys Res Commun; 2023 Jun; 662():126-134. PubMed ID: 37104883
[TBL] [Abstract][Full Text] [Related]
13. The Forkhead box transcription factor FOXM1 is required for the maintenance of cell proliferation and protection against oxidative stress in human embryonic stem cells.
Kwok CT; Leung MH; Qin J; Qin Y; Wang J; Lee YL; Yao KM
Stem Cell Res; 2016 May; 16(3):651-61. PubMed ID: 27062359
[TBL] [Abstract][Full Text] [Related]
14. Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.
Nandi I; Smith HW; Sanguin-Gendreau V; Ji L; Pacis A; Papavasiliou V; Zuo D; Nam S; Attalla SS; Kim SH; Lusson S; Kuasne H; Fortier AM; Savage P; Martinez Ramirez C; Park M; Katzenellenbogen JA; Katzenellenbogen BS; Muller WJ
J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36795481
[TBL] [Abstract][Full Text] [Related]
15. Silencing transcription factor FOXM1 represses proliferation, migration, and invasion while inducing apoptosis of liver cancer stem cells by regulating the expression of ALDH2.
Chen L; Wu M; Ji C; Yuan M; Liu C; Yin Q
IUBMB Life; 2020 Feb; 72(2):285-295. PubMed ID: 31580537
[TBL] [Abstract][Full Text] [Related]
16. The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study.
Rossini E; Tamburello M; Abate A; Zini S; Ribaudo G; Gianoncelli A; Calza S; Valcamonico F; Suardi NR; Mirabella G; Berruti A; Sigala S
Cells; 2024 Feb; 13(5):. PubMed ID: 38474332
[TBL] [Abstract][Full Text] [Related]
17. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
[TBL] [Abstract][Full Text] [Related]
18. Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
Tan Y; Wang Q; Xie Y; Qiao X; Zhang S; Wang Y; Yang Y; Zhang B
Int J Oncol; 2019 Jan; 54(1):87-97. PubMed ID: 30365046
[TBL] [Abstract][Full Text] [Related]
19. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Floros KV; Jacob S; Kurupi R; Fairchild CK; Hu B; Puchalapalli M; E Koblinski J; Dozmorov MG; Boikos SA; Scaltriti M; Faber AC
Cell Death Dis; 2021 Feb; 12(2):179. PubMed ID: 33589591
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated FOXM1 signaling in the regulation of cancer stem cells.
Sher G; Masoodi T; Patil K; Akhtar S; Kuttikrishnan S; Ahmad A; Uddin S
Semin Cancer Biol; 2022 Nov; 86(Pt 3):107-121. PubMed ID: 35931301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
